Skip to main navigation
Skip to search
Skip to main content
University of Galway Home
Help & FAQ
Link opens in a new tab
Search content at University of Galway
Home
Profiles
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Courses
Blinatumomab for the treatment of acute lymphoblastic leukemia
Jason B. Kaplan
, Marina Grischenko
, Francis J. Giles
Northwestern University Feinberg School of Medicine
Northwestern Medicine
Research output
:
Contribution to a Journal (Peer & Non Peer)
›
Review article
›
peer-review
31
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Blinatumomab for the treatment of acute lymphoblastic leukemia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
B Cell
50%
CD3 Antigen
50%
Pharmacokinetics
33%
T Cell
33%
Clinical Study
33%
Intravenous Drug Administration
33%
Malignant Neoplasm
16%
Arm
16%
Programmed Cell Death
16%
Clinical Trial
16%
Precursor
16%
Pharmacodynamics
16%
Metabolism
16%
Cell Surface
16%
Spontaneous Remission
16%
Neurotoxicity
16%
Diseases
16%
Philadelphia 1 Chromosome
16%
Risk Evaluation
16%
Chemotherapy
16%
Treatment Option
16%
Antigen
16%
Lymphoid Progenitor Cell
16%
Granzyme
16%
Cytokine Release Syndrome
16%
Perforin
16%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Blinatumomab
100%
CD3 Antigen
50%
Clinical Study
33%
Pharmacokinetics
33%
Malignant Neoplasm
16%
Clinical Trial
16%
Drug Development
16%
Pharmacodynamics
16%
Chemotherapy Regimens
16%
Preclinical Study
16%
Remission
16%
Neurotoxicity
16%
Diseases
16%
Philadelphia 1 Chromosome
16%
Granzyme
16%
Cytokine Release Syndrome
16%
Risk Evaluation
16%
Perforin
16%
Preclinical Pharmacology
16%
Antigen
16%